Cutaneous adverse events ‘common’ with PI3-K inhibitors
Nearly a third of patients with cancer treated with phosphoinositide 3-kinase inhibitors have cutaneous adverse events of any grade, according to findings from a review of more than a dozen clinical trials.
In addition, the study shows the rate of severe cutaneous adverse events (grade 3 or higher) among those given phosphoinositide 3-kinase (PI3K) inhibitors, including idelalisib and alpelisib, is an estimated 7%, US researchers say.